Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Black Diamond ,Arizona ,American ,Nader Sanai ,Patrick Wen ,Mario Corso ,Nasdaq ,Ivy Brain Tumor Center ,International Conference On Molecular ,Globenewswire Inc ,Exchange Commission ,American Society Of Clinical Oncology ,Diamond Therapeutics Inc ,Dana Farber Cancer Institute ,Company Masterkey ,Diamond Therapeutics ,Clinical Oncology ,Farber Cancer ,Generation Covalent ,Recurrent Glioblastoma ,Dose Escalation Results ,Molecular Targets ,Trigger Trial ,Recurrent High Grade Glioma ,Ivy Brain Tumor ,Private Securities Litigation Reform Act ,Annual Report ,States Securities ,Investor Relations ,